Organization type


  • Pharma

Early phases


  • Target identification – new biological hypothesis
  • Target validation – Hypothesis verification

Screening


  • Assay development
    • In vitro screening models
    • In vivo screening models
  • Chemical libraries
    • Small molecules (including natural product, DNA encoded libraries and fragment libraries)
  • Fragment based screening
    • Hit expansion. Medicinal chemistry programs.
    • Virtual screening
  • Screening and high throughput screening using small molecules (including natural product, DNA encoded libraries and fragment libraries)

Optimization phases


  • In vitro biochemical models(including assay/model development and testing)
  • In vitro cellular and organotypic 3D models (including assay/model development and testing)
  • In vivo animal models (including assay/model development and testing)
  • Medicinal chemistry programs for hit to lead and lead optimization
  • Preclinical phase (including assay/model development and testing)(non-regulatory and regulatory)
    • ADME / DMPK

Functional areas


  • Compound management
  • Molecular and cellular biology
    • Cell line generation
    • Flow cytometry
    • Gene editing
    • qPCR

Terapeutic areas


  • Dermatology